Drugs / etimicin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT03380793 Background | Sep 2016 → Oct 2018 | appendicitis | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | etimicin | “morinidazole and sodium chloride injection (500 mg intravenous, twice daily for 5-7 days) with aztreonam and (or) etimicin.” NCT03380793 ↗ |